Inventor · disambiguated record
Lorin K. Johnson
Also filed as: JOHNSON LORIN · JOHNSON LORIN K
20 granted patents·19 pending applications·631 citations·filing 1984–2025
96Inventor score
Files withSALIX PHARMACEUTICALS INC8FORBES WILLIAM5BIOTECHNOLOGY RES ASS4JOHNSON LORIN4SALIX PHARMACEUTICALS LTD4
Top patents by PatentIndex Score
39 records- 0196US7452872B2Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivativesSALIX PHARMACEUTICALS INC·Filed 2007·Granted Nov 18, 2008·39 cites·20 claims
- 0294US8309569B2Methods for treating diarrhea-associated irritable bowel syndromeFORBES WILLIAM·Filed 2009·Granted Nov 13, 2012·25 cites·2 claims
- 0392US4764504ANovel atrial natriuretic/vasodilator polypeptidesBIOTECHNOLOGY RES ASS·Filed 1985·Granted Aug 16, 1988·195 cites·4 claims
- 0490US9192616B2Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivativesJOHNSON LORIN·Filed 2012·Granted Nov 24, 2015·15 cites·24 claims
- 0588US4757048ASynthetic analogs of atrial natriuretic peptidesBIOTECHNOLOGY RES ASS·Filed 1986·Granted Jul 12, 1988·70 cites·9 claims
- 0687US7625884B2Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivativesSALIX PHARMACEUTICALS LTD·Filed 2007·Granted Dec 1, 2009·7 cites·9 claims
- 0786US8497256B2Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of malesFORBES WILLIAM·Filed 2011·Granted Jul 30, 2013·3 cites·35 claims
- 0884US4935492ACyclic analogs of atrial natriuretic peptidesCALIFORNIA BIOTECHNOLOGY INC·Filed 1988·Granted Jun 19, 1990·53 cites·20 claims
- 0980US4804650AAnalogs of atrial natriuretic peptidesBIOTECHNOLOGY RES ASS·Filed 1988·Granted Feb 14, 1989·39 cites·5 claims
- 1078US5019508ASynovial phospholipasesBIOTECH RES PARTNERS LTD·Filed 1988·Granted May 28, 1991·45 cites·25 claims
- 1176US2023181571A1Use of methylnaltrexone to attenuate tumor progressionSALIX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1274US2020163958A1Use of methylnaltrexone to attenuate tumor progressionSALIX PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1373US5498608AUse of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agentsSALIX PHARMACEUTICALS·Filed 1994·Granted Mar 12, 1996·40 cites·5 claims
- 1469US2015132381A1Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of malesFORBES WILLIAM·Filed 2014·Application pending·0 cites
- 1569US2021121456A1Use of methylnaltrexone to attenuate tumor progressionSALIX PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1668US4618600ANovel polypeptide diuretic/vasodilatorsBIOTECHNOLOGY RES ASS·Filed 1984·Granted Oct 21, 1986·20 cites·10 claims
- 1768US2010087401A1Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivativesSALIX PHARMACEUTICALS LTD·Filed 2009·Application pending·0 cites
- 1864US2013295178A1Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of malesFORBES WILLIAM·Filed 2013·Application pending·0 cites
- 1963US2025186423A1Methods of treating cancer and other conditions with a mu opioid receptor antagonistGLYCYX MOR INC·Filed 2023·Application pending·0 cites
- 2062US5342764ARecombinant expression system for human anti-inflammatory phospholipase inhibitor proteinSCIOS NOVA INC·Filed 1993·Granted Aug 30, 1994·17 cites·8 claims
- 2161US2025312671A1Stationary roping practice target apparatusJOHNSON LORIN·Filed 2025·Application pending·0 cites
- 2260US5905073AUse of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agentsSALIX PHARMACEUTICALS INC·Filed 1995·Granted May 18, 1999·26 cites·9 claims
- 2360US2009324736A1Methods of treating bowel diseases by administering a bowel cleanser and an antibioticSALIX PHARMACEUTICALS LTD·Filed 2009·Application pending·0 cites
- 2459US5047397ALinear analogs of atrial natriuretic peptidesCALIFORNIA BIOTECHNOLOGY INC·Filed 1988·Granted Sep 10, 1991·23 cites·20 claims
- 2557US2016000765A1Methods for treating bowel diseasesSALIX PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2656US2017202832A1Use of methylnaltrexone to attenuate tumor progressionSALIX PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2755US2022119819A1FormulationATLANTIC PHARMACEUTICALS HOLDINGS LTD·Filed 2022·Application pending·0 cites
- 2854US2013137713A1Methods for treating bowel diseasesFORBES WILLIAM·Filed 2012·Application pending·0 cites
- 2954US2022175764A1Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disordersBAUSCH HEALTH IRELAND LTD·Filed 2021·Application pending·0 cites
- 3054US2009252788A1Balsalazide formulations and manufacture and use thereofSALIX PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3149US5552530AAntibodies that specifically bind to and inhibit human synovial phospholipase A2 type ALILLY CO ELI·Filed 1994·Granted Sep 3, 1996·10 cites·8 claims
- 3247US11220690B2FormulationATLANTIC PHARMACEUTICALS HOLDINGS LTD·Filed 2018·Granted Jan 11, 2022·0 cites·23 claims
- 3347US2013164384A1Methods of treating bowel diseases by administering a bowel cleanser and an antibioticJOHNSON LORIN·Filed 2012·Application pending·0 cites
- 3446US8921344B2Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivativesJOHNSON LORIN·Filed 2006·Granted Dec 30, 2014·0 cites·30 claims
- 3544US2011055943A1Novel therapeutic targets in inflammatory bowel diseaseSALIX PHARMACEUTICALS LTD·Filed 2008·Application pending·0 cites
- 3638US5264550AHuman anti-inflammatory phospholipase inhibitor proteinSCIOS NOVA INC·Filed 1992·Granted Nov 23, 1993·3 cites·6 claims
- 3735US2016279153A1Balsalazide formulations and manufacture and use thereofLOCKHART JOSEPH·Filed 2016·Application pending·0 cites
- 3833US5646254AAntibodies for human phospholipase inhibitory protein (hPIP)SCIOS NOVA INC·Filed 1994·Granted Jul 8, 1997·1 cites·2 claims
- 3931US2019388459A1New therapeutic usesATLANTIC PHARMACEUTICALS HOLDINGS LTD·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →